Massive french study reveals gaps in liver cancer screening
NCT ID NCT02983968
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at health insurance records of over 75,000 people with cirrhosis in France to see if doctors follow guidelines for early liver cancer screening. The goal was to find out how often screening is done correctly and what factors might lead to missed or delayed diagnosis. No new treatment was tested; instead, the study aims to improve future screening practices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify gaps in liver cancer screening and improve guidelines to catch cancer earlier.
- What could go wrong
- This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens
Amiens, 80084, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can everyday drugs shield the liver from Cirrhosis's worst threats?
- Could a yellow tinge predict dangerous hospital infections?
- Muscle quality on MRI may foretell liver transplant success
- Melatonin may ease sleep and brain fog in liver disease — a trial puts it to the test
- Heart scans could uncover silent damage in liver patients awaiting transplant
- Could the Body's largest vein replace a Hard-to-Reach one for liver pressure checks?